Coming Soon therascreen ALK RGQ RT-PCR Kit
For sensitive detection of clinically relevant ALK fusions via ALK kinase domain mRNA expression from FFPE tissue samples
The therascreen ALK RGQ RT-PCR Kit is a ready-to-use in vitro diagnostic test for the detection of ALK fusions in lung cancer patients via ALK kinase domain mRNA expression. Using Scorpions detection technology, the kit provides all necessary reagents optimized for rapid and sensitive detection of even low levels of ALK kinase domain mRNA and ABL1 mRNA expression using real-time RT-PCR on the Rotor-Gene Q MDx 5Plex HRM Instrument. The assay uses ABL1 expression as an endogenous internal control.
The therascreen ALK RGQ RT-PCR Kit is a ready-to-use kit for the detection of ALK kinase domain mRNA expression and ABL1 mRNA expression using multiplex, one-step RT-PCR on the QIAGEN Rotor-Gene Q MDx 5Plex HRM Platform. The anaplastic lymphoma kinase (ALK) gene encodes a receptor tyrosine kinase, which belongs to the insulin receptor superfamily. This gene has been found to be rearranged, mutated or amplified in a series of tumors including non-small cell lung cancer. The chromosomal rearrangements are the most common genetic alterations in this gene.
The kit enables qualitative measurement of ALK kinase domain mRNA expression and ABL1 mRNA expression from total RNA extracted from formalin-fixed paraffin-embedded (FFPE) patient samples.
The therascreen ALK RGQ RT-PCR Kit comprises a one-step procedure in which reverse transcription and PCR are performed in the same reaction tube for expression detection of both ALK kinase domain mRNA and ABL1 mRNA. ABL1 is an endogenous control that monitors the quantity and quality of RNA used, and controls for the presence of inhibitors that may lead to false negative results. The patient result and control result are both conveniently obtained in a single reaction.
The therascreen ALK RGQ RT-PCR Kit is for in vitro diagnostic (IVD) use. This kit is CE-marked and fulfills the requirements of the European Directive 98/79/EC for in vitro diagnostic medical devices. The therascreen ALK RGQ RT-PCR Kit is based on real-time PCR technology and enables detection of clinically relevant ALK fusions in solid tumor tissue from lung cancer patients via ALK kinase domain mRNA expression.
fragment fix placeholder